©2024 Stanford Medicine
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Recruiting
Trial ID: NCT04308681
Purpose
The purpose of this study is to provide an initial evaluation of the effectiveness of
BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and
provide information on the drug levels of BMS-986278 in these participants.
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
Stanford Investigator(s)
Rishi Raj
Clinical Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Eligibility
Inclusion Criteria:
For the idiopathic pulmonary fibrosis (IPF) Cohort
- Diagnosis of IPF within 7 years of screening
- Female and males ≥ 40 years of age
For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
- Evidence of progressive ILD within the 24 months before screening
- Female and male ≥ 21 years of age.
Exclusion Criteria:
- Women of childbearing potential (WOCBP)
- Active Smokers
- Current malignancy or previous malignancy up to 5 years prior to screening
- History of allergy to BMS-986278 or related compounds
Other protocol-defined inclusion/exclusion criteria apply
Intervention(s):
other: BMS-986278 Placebo
drug: BMS-986278
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Rishi Raj, Site 0043
650-736-8083